Sionna Therapeutics (SION) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Voting matters and shareholder proposals
Four class II directors are up for election to serve until the 2029 annual meeting or until a successor is duly elected and qualified, or earlier death, resignation, or removal.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is proposed.
Proxies are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Director nominees include H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D.
Audit committee and external auditor matters
Deloitte & Touche LLP is recommended for ratification as the independent registered public accounting firm for the 2026 fiscal year.
Latest events from Sionna Therapeutics
- SION-719 failed in Phase 2a, while SION-451 + SION-2222 met Phase 1 safety and PK goals.SION
Study result - Net loss rose to $56.7M as R&D spending grew; cash reserves support operations into 2028.SION
Q2 2026 - Advancing NBD1-targeted therapies for CF with pivotal clinical data expected in 2026.SION
Corporate presentation - Summer 2026 data will determine the future of NBD1 stabilizer programs in cystic fibrosis.SION
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Pivotal data for two differentiated NBD1-targeting CF therapies expected in summer 2026.SION
Jefferies Global Healthcare Conference 2026 - Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy.SION
RBC Capital Markets Global Healthcare Conference 2026 - Q1 2026 net loss rose to $26.8M; cash reserves fund operations into 2028, topline data due summer 2026.SION
Q1 2026 - Lead NBD1 stabilizers show promise to transform CF care, with pivotal data expected summer 2026.SION
Corporate presentation - Advancing two NBD1 stabilizers for cystic fibrosis, with pivotal data expected by mid-2026.SION
Cantor Global Healthcare Conference 2025